Advertisement

Effect of percutaneous endoscopic gastrojejunostomy tube placement on levodopa pharmacokinetics

  • Noriyuki MiyaueEmail author
  • Hayato Yabe
  • Masahiro Nomoto
  • Masahiro Nagai
Letter to the Editor
  • 16 Downloads

Most patients with Parkinson’s disease (PD) experience motor fluctuations, including the wearing-off phenomenon, in the advanced stage. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG) via percutaneous endoscopic gastrojejunostomy (PEG-J) helps maintain adequate plasma concentrations of levodopa and ameliorates the motor fluctuations in patients with advanced PD. A recent study reported an effective long-term maintenance of the motor symptoms in patients with PD who received LCIG treatment [1]. However, complications related to the tube and pump are common, occasionally necessitating withdrawal of the LCIG treatment [2].

We present the case of a 71-year-old female with PD, who was the subject of a previous report on the relationship between a cascade stomach, which is a functional deformity of stomach with biloculation of the gastric cavity, and the levodopa pharmacokinetics [3]. The patient exhibited motor fluctuations, such as wearing-off phenomenon and...

Notes

Author contributions

NM and HY were involved in conception and designed the study. NM was involved in acquisition and analysis of the data. NM drafted the manuscript and HY, MNagai, MNomoto critically revised the manuscript. All authors gave the final approval of the manuscript to be published.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical compliance statement

The patient provided informed consent for publication. The authors confirm that the approval of an institutional review board was not required for this work. We confirm that we have read the Journal’s policy on ethical publication and affirm that this work is consistent with those guidelines.

Informed consent

Informed consent was obtained from the participant included in the study.

References

  1. 1.
    Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ (2018) Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease. Mov Disord 33(6):928–936.  https://doi.org/10.1002/mds.27338 CrossRefGoogle Scholar
  2. 2.
    Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30(4):500–509.  https://doi.org/10.1002/mds.26123 CrossRefGoogle Scholar
  3. 3.
    Miyaue N, Tada S, Ando R, Yabe H, Nishikawa N, Nagai M, Nomoto M (2017) Cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson’s disease. Mov Disord 32(10):1492–1493.  https://doi.org/10.1002/mds.27109 CrossRefGoogle Scholar
  4. 4.
    Chan PL, Nutt JG, Holford NH (2005) Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson’s disease. J Pharmacokinet Pharmacodyn 32(3–4):307–331.  https://doi.org/10.1007/s10928-005-0039-x CrossRefGoogle Scholar
  5. 5.
    Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study investigators and coordinators (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 21(3):231–235.  https://doi.org/10.1016/j.parkreldis.2014.12.012 CrossRefGoogle Scholar
  6. 6.
    Udd M, Lyytinen J, Eerola-Rautio J, Kenttämies A, Lindström O, Kylänpää L, Pekkonen E (2017) Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease. Brain Behav 7(7):e00737.  https://doi.org/10.1002/brb3.737 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurology and Clinical PharmacologyEhime University Graduate School of MedicineTohonJapan
  2. 2.Department of NeurologySaiseikai Matsuyama HospitalMatsuyamaJapan
  3. 3.Department of NeurologySaiseikai Imabari HospitalImabariJapan

Personalised recommendations